Pretomanid and Sitagliptin
Determining the interaction of Pretomanid and Sitagliptin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with pretomanid may significantly increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3). The proposed mechanism, based on in vitro data, is decreased clearance due to pretomanid-mediated inhibition of OAT3. No clinical interaction studies have been conducted in humans with OAT3 substrates. MANAGEMENT: Caution is advised if pretomanid is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate drug should be considered whenever pretomanid is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.
Professional:MONITOR: Coadministration with pretomanid may significantly increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3). The proposed mechanism, based on in vitro data, is decreased clearance due to pretomanid-mediated inhibition of OAT3. No clinical interaction studies have been conducted in humans with OAT3 substrates.
MANAGEMENT: Caution is advised if pretomanid is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate drug should be considered whenever pretomanid is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.
Generic Name: sitagliptin
Brand name: Januvia
Synonyms: SitaGLIPtin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pretomanid-Sitagliptin and metformin
- Pretomanid-Sitagliptin and Metformin Extended-Release Tablets
- Pretomanid-Sitagliptin and Metformin Tablets
- Pretomanid-Sitagliptin and simvastatin
- Pretomanid-Sitagliptin Phosphate
- Pretomanid-Sitavig
- Sitagliptin-Pretomanid Tablets
- Sitagliptin-Pretz-D
- Sitagliptin-Prevacid
- Sitagliptin-Prevacid 24 HR
- Sitagliptin-Prevacid Injection
- Sitagliptin-Prevacid Naprapac